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Human blood derived in vitro differentiated monocytes or macrophages are a population of cells which have been investigated over
the years to determine the role these cells play in the resolution phase of gout. Macrophages are able to phagocytose monosodium
urate monohydrate (MSU) crystals without releasing inflammatory factors. This study analysed macrophage platelet activating
factor secretion and its possible role in the pathway of gout resolution.Analysis of sunatants from in vitrodifferentiatedmacrophages
stimulated withMSU crystals revealed the secretion of platelet activating factor (PAF) 1.54±0.10mean ± SEM; ng/mL per 106 cells.
This secretion was absent in immature monocytes treated similarly. When these monocytes were pretreated with recombinant
human PAF-acetylhydrolase (rhuPAF-AH) and MSU crystals resulted in TNF𝛼 suppression. Addition of WEB2086, a platelet
activating factor (PAF) antagonist, to differentiated macrophages with MSU crystals unmasked TNF𝛼 secretion 0.7 ± 0.06mean ±
SEM; ng/mL per 106 cells.This study identifies a role for PAF and the PAF receptor antagonist in the pathway by whichmacrophages
ingest MSU crystals and resolve the concomitant inflammation.
1. Introduction
An acute attack of gouty arthritis includes clinical features
such as joint inflammation, erythema, fever, and extreme,
unbearable pain resulting in reduced mobility of the afflicted
joint [1]. Prophylactic therapy is recommended to control
gouty arthritis flares [2, 3]. The symptoms are caused by
monosodium urate monohydrate (MSU) crystal deposition
into the intra-articular joint spaces. Crystal precipitation
provokes mass polymorphonuclear (PMN) leukocyte infil-
tration into the joints where these cells release inflammatory
cytokines which mediate joint damage [4, 5]. However, in the
absence of clinical intervention, gout is self-limiting in nature
and is able to spontaneously resolve over a period of a week
[6–9]. The exact theory behind the resolution phase of gout
remains an enigma althoughmacrophages and their cofactors
have been implicated in the mechanism [10–12].
Platelet activating factor (PAF, 1-0-alkyl-2-acetyl-sn-glyc-
ero-3-phosphocholine) was discovered in 1972, it is known
as one of the most potent phospholipids, involved in
platelet aggregation and anaphylaxis [13]. It is produced by
a variety of immune cells includingmonocytes/macrophages,
neutrophils, eosinophils, basophils, and platelets [14, 15].
There are two main pathways which lead to cellular synthesis
of PAF, the de nova pathway and remodelling pathway.
Inflammatory or immune stimuli induce PAF primarily via
the remodelling pathway whereby membrane bound PAF-
acetylhydrolase (PAF-AH) which is an extracellular phos-
pholipase A2 catalyses the transfer of an acetyl residue from
acetyl-CoA to 1-alkyl-sn-glycero-3-phosphocholine (lyso-
PAF). This is produced by the action of phospholipase A2 on
phosphatidylcholine [16–18].
However, the full mechanisms and the exact role of
various enzymes on PAF degradation have not been fully
elucidated to date.
To exert its effect, PAF binds directly to a specific G
protein coupled receptor and is an important mediator of
juxtacrine and paracrine signals between cells [19]. PAF is
well regarded as a potent mediator of inflammatory patholo-
gies such as acute pancreatitis [20], diabetes [21], and renal
failure [22]. However, recent studies suggest PAF could also
play a crucial role in regulating immune responses. Studies
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have highlighted the necessity of PAF receptor activation
in deactivation of ultraviolet B (UVB) induced suppres-
sion of hypersensitivity responses [23]. In addition, PAF
administration to equine alveolar macrophages increased
phagocytic capacity and superoxide anion production [24].
Moreover, during immunological defence, PAF can play an
immunomodulatory role includingmonocyte ormacrophage
degranulation, cytokine release, phagocytosis, and cell adhe-
sion [25, 26].
2. Materials and Methods
2.1. Reagents and Antibodies. WEB2086 was purchased from
Tocris Bioscience (UK). Human TNF𝛼 ELISA kit was pur-
chased from R and D systems Europe. PAF ELISA kit was
purchased from Blue Gene Biotech, China. LPS, antimono-
clonal anti-human CD62, anti-mouse IgG FITC, and mouse
IgG1 were purchased from Sigma-Aldrich (Poole, UK). MSU
crystals were purchased from Enzo Life Sciences, Germany.
HUVEC cells were purchased from ATCC cell lines, UK.
Recombinant human PAF-acetylhydrolase was purchased
from Sigma-Aldrich, USA.
2.2.Monocyte Isolation Procedure. Leucocyte rich cones were
obtained from volunteer donors collected from NHS Cord
Blood and Transplant Bank at Colindale, London. Briefly,
the cones were washed with PBS to harvest leucocytes.
The leucocyte rich cells were then spun on Histopaque
at 1200 RPM for 20 mins. The mononuclear portion was
obtained and washed in HANKS balanced solution. Cells
were counted and cultured into 24 wells at 4 × 106/mL. Cells
were allowed to adhere for an hour after which nonadherent
cells were washed and full media replenished with Dulbecco’s
media containing AB serum. Differentiated macrophages
were determined by light microscopy and flow cytometry
phenotypic analysis of differentiation markers. Cells were
washed and fed at days 1, 3, 5, and 7 of culture and stimulated
with LPS (10𝜇g/mL) or MSU crystals (0.5mg/mL) with or
without pretreatment with WEB2086 for 16–24 hours after
which supernatants were collected and stored in aliquots at
−70∘C prior to analysis. Pretreatment with rhuPAF-AH at
concentrations of 2.5–20𝜇g/mL was carried out for half an
hour prior to addition of MSU crystals to monocyte cells.
Supernatants were collected and analysed for TNF𝛼 after
16 hours.
2.3. Enzyme Linked Immunosorbant Assays (ELISA). PAF
and TNF𝛼 levels in cultured supernatants were determined
by ELISA (purchased from Blue Gene Biotech, China,
and R and D Systems Europe, resp.) using manufacturer’s
recommendations. For PAF determination, culture super-
natants were pretreated with balance solution provided in the
ELISA kit, mixed, and then processed according to manu-
facturer’s instructions. The antibodies to PAF formed solid
phase ELISA. All samples were measured in duplicate, with
results expressed as the mean ± SEM cytokine concentration
(ng/mL) from at least 4 experiments.
2.4. Flow Cytometric Analysis. Indirect flow cytometric anal-
ysis was performed as previously described (12), using
primary antibodies at 10 𝜇g/mL and secondary antibod-
ies at 1 : 64 dilution. Endothelial cells were detached by
trypsin/EDTA and the trypsin activity was quenched in
excess growth medium supplemented with serum. Mono-
cyte/macrophage cultures were detached by 15-minute incu-
bation in ice-cold phosphate buffered saline (PBS) contain-
ing 2.5mM of EDTA, followed by scraping and washing
in growth medium containing serum. Data analysis was
performed using a flow cytometer analyser purchased from
Beckton Dickinson (BD), UK. Results were analysed using
BD Cell Quest Pro software.
HUVECE-Selectin expression was calculated by dividing
the staining intensity (mean fluorescent intensity (MFI)) of
E-Selectin by the staining intensity of class-matched control
antibody, thus resulting in a relative fluorescent intensity
(RFI) of expression (where an RFI of 1.00 is equivalent to no
antigen expression). Results were expressed as themean ± SD
RFI from at least 3 separate experiments.
2.5. Statistical Analysis. Analysis of inhibition by WEB2086
on TNF𝛼 secretion and endothelial cell E-Selectin expression
was carried out using 1-way analysis of variance (ANOVA)
with Dunnett’s correction.
3. Results and Discussion
Figure 1 shows that monocytes secrete detectable PAF when
incubated withMSU crystals.This detection of PAF occurs at
day 5 and peaks at day 7 ofmonocyte differentiation.The phe-
notype of monocytes as they differentiate into macrophages
has been well characterised and it has previously been postu-
lated that they can acquire an anti-inflammatory phenotype.
A similarmodel showed that at days 5–7 ofmonocyte culture,
upon stimulation with MSU crystals, an anti-inflammatory
phenotypic response was enabled [11]. This was corroborated
by the detection of TGF𝛽1 secretion by human in vitro differ-
entiated macrophages in response to MSU crystal challenge.
Coincubation of day 7 in vitro differentiated macrophages
with the PAF receptor antagonist (WEB2086) and MSU
crystals resulted in a decrease in PAF secretion (Figure 2). To
investigate whether PAF production was autocrine suppres-
sive, MSU crystal stimulated macrophages were incubated
in the presence of increasing concentrations of the PAF
receptor antagonist and this time TNF𝛼 production was
analysed. Inclusion of WEB2086 at concentrations of 25–
100 𝜇M in these cultures resulted in peak TNF𝛼 production
(Figure 3(b)). In fact, this TNF𝛼 production was comparable
to that released by day 1 monocytes after MSU crystal
stimulation which had been determined in a previous study
[11].
Prior investigations have reported that macrophage
cell lines and human in vitro differentiated macrophages
can ingest MSU crystals without releasing inflammatory
cytokines (TNF𝛼, IL-1𝛽, and IL-6) [11, 12]; indeed, it was iden-
tified that instead macrophages produced anti-inflammatory
TGF𝛽1. In addition, it was observed that TGF𝛽1 was able to
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Figure 1: Monocyte differentiation and time course of platelet acti-
vating factor (PAF) production after challenge with MSU crystals.
Isolated monocytes were differentiated over 7 days in vitro and
incubated with MSU crystals for 17 hours at day 1 (D1), day 3 (D3),
day 5 (D5), and day 7 (D7) of culture. Collected supernatants were
analysed for PAF secretion by ELISA. Results are mean and SEM of
4 experiments.
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Figure 2: Platelet activating factor (PAF) production by D7 in vitro
differentiated macrophages incubated with MSU crystals and with
or without WEB2086 (WEB). Monocytes were cultured for 1 and 7
days and stimulated with MSU crystals and collected supernatants
were analysed for PAF by ELISA. Results are mean and SEM of
4 experiments. D7 = supernatants from day 7 macrophages, D1 =
supernatants from day 1 Monocytes, and WEB = WEB2086.
Macrophages also secreted PAF when incubated with LPS (1.48 ±
0.10mean ± SEM; ng/mL per 106 cells), data not shown.
inhibit endothelial cell activation and E-Selectin expression
[12]. Essentially in this study coincubation of endothelial cells
with anti-TGF𝛽1 and amixture of day 1 and day 7MSUcrystal
stimulated supernatants unmasked only a partial degree of
endothelial E-Selectin reexpression even with using maxi-
mum concentrations of neutralising antibody against TGF𝛽1.
This suggested that other anti-inflammatory factors could
also be released by macrophages upon phagocytosis of MSU
crystals. Figures 1 and 2 identify macrophage derived PAF in
this mechanism. Another anti-inflammatory model whereby
macrophages play an active role in regulating inflammation
and resulting in PAF mediated activity by macrophages
is the phagocytosis of apoptotic neutrophils. Indeed, this
mechanism also results in a lack of proinflammatory cytokine
release and associated inflammation [27–29]. Pretreatment
of freshly isolated monocytes with rhuPAF-AH and MSU
crystals resulted in partial suppression of TNF𝛼 release. Full
suppression of TNF𝛼 was not expected as manufacturers
reference data indicated that rhuPAF-AH cleaved the PAF
analogue by approximately 50% at 10 𝜇g/mL, which was
observed in Figure 3(a).
It is likely that PAF exerts an immunomodulatory effect
on MSU crystal stimulated macrophages as coincubation
in the presence of WEB2086 unmasked TNF𝛼 production,
implicating that PAF may be involved in autocrine and
paracrine suppression of macrophages.
There are studies that highlight PAF’s role in endocrine,
autocrine, and intercrine signalling [28]. Endothelial activa-
tion precedes the inflammatory response by MSU crystals
which has been observed in vitro and in vivo [27]. An
antagonist of PAF was able to reduce E-Selectin medi-
ated endothelial activation (Figure 4). Although PAF is well
regarded as a potent mediator of inflammation, emerging
research suggests that PAF canmediate inflammation control
[30–32]. Impaired anaphylactic responses were reported in
mice lacking the PAF receptor [23, 26]. Another study showed
thatmice stimulatedwith LPSwere protected from endotoxin
shock when injected with PAF systemically. In these mice,
a reduction in proinflammatory cytokine secretion, namely,
interferon gamma, IL-1, and TNF𝛼, was also observed [32].
Researchers have highlighted the role of PAF mediated
interference in microbial associated damage as well. PAF was
pivotal in the extent of pathological consequences due to H.
pylori infection and gastric mucin synthesis [33]. Another
report implicated PAF in Porphyromonas gingivalis, LPS
mediated interference with salivary mucin [34]. Moreover,
prophylactic administration of PAF antagonist to rats with
gastric injury exerted an anti-inflammatory effect reducing
mucosal apoptosis, TNF𝛼, and nitric oxide synthase 2 activity
and resulted in rapid gastric ulcer healing [35].
In fact, PAF has been identified as a molecular sensor
recognising cellular damage and exerting effects on cytokines
and COX-2 transcription which resulted in systemic immune
suppression [36]. Deposition of MSU crystals into intra-
articular joints causes joint swelling and joint damage as well
as oxidative stress [2, 3, 5, 37]. Hence, it is feasible that a
similar sensory mechanism of cell damage detection by PAF
and PAF receptor signalling could be underpinning gouty
arthritis.
4. Conclusion
This study identifies macrophage derived PAF and PAF
related molecules in the noninflammatory phagocytosis
of MSU crystals by human blood derived differentiated
macrophages. In this model, the PAF receptor antagonist
was able to have a number of effects; it was able to
inhibit endothelial cell activation measured by E-Selectin
4 International Journal of Inflammation
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
M
SU
M
SU
 +
2
.5
𝜇
g/
m
L
rh
uP
A
F-
A
H
M
SU
 +
5
𝜇
g/
m
L
rh
uP
A
F-
A
H
M
SU
 +
1
0
𝜇
g/
m
L
rh
uP
A
F-
A
H
M
SU
 +
2
0
𝜇
g/
m
L
rh
uP
A
F-
A
H
TN
F𝛼
(n
g/
m
L)
(a)
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
D
7
+ 
M
SU
D
7
+ 
M
SU
 +
 W
EB
1
0
0
𝜇
M
D
7
+ 
M
SU
 +
 W
EB
5
0
𝜇
M
D
7
+ 
M
SU
 +
 W
EB
2
5
𝜇
M
TN
F𝛼
(n
g/
m
L)
(b)
Figure 3: (a) Effect of recombinant human platelet activating factor acetylhydrolase (rhuPAF-AH) on TNF𝛼 release frommonocytes. Freshly
isolated monocytes were cultured overnight and treated with rhuPAF-AH at concentrations of 2.5, 5, 10, and 20𝜇g/mL, respectively, for
45 minutes prior to addition of MSU crystals for 24 hours. Afterwards, collected supernatants were analysed for TNF𝛼 by ELISA. Results
are mean and SEM of 3 experiments. (b). TNF𝛼 production unmasked by costimulation of in vitro differentiated macrophages with MSU
crystals and WEB2086. Monocytes were cultured in vitro for 7 days and stimulated with MSU crystals for 24 hours with or without the PAF
antagonist (WEB2086). At 100 𝜇M, coincubation with WEB2086 and urate crystals caused the release of TNF𝛼 with 𝑃 = 0.002 (Student’s
paired 𝑡-test). Conditioned supernatants were analysed for TNF𝛼 production by ELISA. Differentiated macrophages were also coincubated
with WEB2086 at 100𝜇M which reduced the amount of TNF𝛼 unmasked. Values are mean and SEM of 4 experiments. D7 = supernatants
from day 7 macrophages, D1 = supernatants from day 1 monocytes, and WEB =WEB2086 (PAF antagonist).
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Figure 4: Inhibition of endothelial cell activation by platelet
activating factor derived from supernatants from MSU crystal
stimulated macrophages. Monocytes or macrophages were cultured
for 1 and 7 days, respectively, and stimulated with MSU crystals.
Collected supernatants were cocultured with human umbilical vein
endothelial cells (HUVEC) for 4 hours at a 1 : 2 dilution or 1 : 1
mix, either alone or in the presence of WEB2086 (a PAF receptor
antagonist). HUVEC expression of E-Selectin was measured by
flow cytometry. WEB2086 was added to supernatant mixtures in
culture at 100𝜇M which relieved the suppression of E-Selectin
seen in the 1 : 1 mix condition (𝑃 = 0.008 by Student’s paired 𝑡-
test). Relief of E-Selectin suppression by supernatants from day
7 macrophages stimulated with MSU crystals was also observed
(𝑃 = 0.02 by Student’s paired 𝑡-test). Results are the mean and
SD of 3 experiments. RFI = relative fluorescence intensity. D7 =
supernatants from day 7 macrophages, D1 = supernatants from day
1 monocytes, and WEB =WEB2086.
upregulation and was also implicated in downregulating
TNF𝛼 secretion by MSU crystal stimulated monocyte cells.
Essentially, the immune response to MSU crystals is clearly
multifaceted in nature involving a complex interplay by
inflammatory and noninflammatory mechanisms involving
various leukocyte derived factors which act in coordination
during the resolution phase of gouty arthritis. Noticeably, lit-
tle is known about the role that PAF-acetylhydrolases play in
PAF activation and degradation or how PAF exerts its effects
through its receptors. These pathways remain to be defined.
The model of monocyte, macrophage, and MSU crystal
induced inflammation could be used to further examine
these molecular mechanisms and unravel the associated PAF
signalling and receptor pathways. In conclusion, this study
suggests a role for PAF and related molecules in the anti-
inflammatory pathway by which macrophages phagocytose
MSU crystals.
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